anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Problem Agitate Solution

Arc collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 26,550
Current window 20,881-20,910
Pages 885
Rows per page 30
Arc: Problem Agitate Solutionclear collectionreset all
18 30 60

Arc

20,881-20,910 of 26,550

filter-aware
13
Includes a table of PFS events, median PFS, and adjusted hazard ratio (HR) alongside the survival plot and risk table.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Quick Win Big Bet1 hit
14
Includes a risk table and summary statistics table (Median PFS, HR).AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Quick Win Big Bet1 hit
15
Includes risk tables and hazard ratios (HR) with 95% confidence intervals.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Quick Win Big Bet1 hit
16
Includes a forest plot for subgroup analysis and a summary table for prior treatments.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Quick Win Big Bet1 hit
17
The slide uses a mirrored bar chart to compare adverse event frequencies by grade, alongside a summary table of clinical safety outcomes.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Quick Win Big Bet1 hit
18
AstraZeneca | Investor Event Presentation Deck | 42 slidesAstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Quick Win Big Bet1 hit
19
Includes corporate branding, speaker name/title, and scientific imagery.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & Proof1 hit
20
The diagram illustrates a randomized clinical trial flow.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & Proof1 hit
21
The slide presents clinical trial baseline data, likely for a breast cancer study given the markers (ER+, PgR+, ESR1m, CDK4/6i).AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & Proof1 hit
22
The slide uses a standard Kaplan-Meier survival analysis framework common in oncology clinical trials.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Before After1 hit
23
Clinical trial data visualization showing hazard ratios and median PFS.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Before After1 hit
24
Clinical trial data visualization showing progression-free survival (PFS) curves with associated hazard ratios and event counts.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Before After1 hit
25
The slide uses a split-panel design to compare two patient cohorts (ESR1m detectable vs not detectable).AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Before After1 hit
26
Clinical trial data visualization showing hazard ratios and median PFS.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & Proof1 hit
27
The table compares adverse event (AE) frequencies, treatment-related AEs (TRAEs), and dose modifications.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & Proof1 hit
28
The table lists 15 specific adverse events plus 'Any AE' across 4 cohorts, with two columns per cohort (All grades, Grade >=3).AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & Proof1 hit
29
The slide summarizes the primary outcomes of the SERENA-2 trial, confirming PFS benefits and safety, and mentions ongoing Phase III trials (SERENA-4 and SERENA-6).AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & Proof1 hit
30
SABCS stands for San Antonio Breast Cancer Symposium.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
31
Includes Kaplan-Meier survival curve and key efficacy metrics.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
32
Includes a waterfall plot for the BEGONIA trial.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
33
AstraZeneca | Investor Event Presentation Deck | 42 slidesAstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
34
The slide uses a visual layout with three circular metrics to emphasize the scale of the problem.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Confession1 hit
35
The slide uses a patient journey/treatment pathway framework to map current standard of care against emerging therapeutic interventions.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Confession1 hit
36
Uses a before-after-bridge structure to frame the problem (poor outcomes) and the solution (Capivasertib).AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Confession1 hit
37
The slide uses a stacked bar chart to show market share evolution over three quarters and bulleted lists to summarize clinical trial outcomes.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
38
AstraZeneca | Investor Event Presentation Deck | 42 slidesAstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
39
AstraZeneca | Investor Event Presentation Deck | 42 slidesAstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
40
AstraZeneca | Investor Event Presentation Deck | 42 slidesAstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
41
Clinical trial baseline characteristics table.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
42
AstraZeneca | Investor Event Presentation Deck | 42 slidesAstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit